Counterpoint: Data first

Nature. 2010 Apr 1;464(7289):679. doi: 10.1038/464679a.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Drug Discovery / methods
  • Drug Discovery / trends*
  • Fusion Proteins, bcr-abl / antagonists & inhibitors
  • Fusion Proteins, bcr-abl / genetics
  • Fusion Proteins, bcr-abl / metabolism
  • Genome, Human / genetics*
  • Genomics / trends
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Neoplasms / drug therapy*
  • Neoplasms / genetics*
  • Piperazines / pharmacology
  • Piperazines / therapeutic use
  • Precision Medicine / trends
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl